Agilysys (AGYS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investo ...

The price trend for OppFi Inc. (OPFI) has been bearish lately and the stock has lost 7.4% over the past four weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street anal ...

Shares of Apogee Therapeutics Inc. (APGE) have gained 41.4% over the past four weeks to close the last trading session at $55.7, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $94.3 indicates a potential upside of 69.3%.The mean estimate comprises 10 short-term price targets with a standard deviation of $16.3. While the lowest estimate of $60.00 indicates a 7.7% increase from t ...

Shares of Relay Therapeutics, Inc. (RLAY) have gained 37.4% over the past four weeks to close the last trading session at $7.31, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.6 indicates a potential upside of 86.1%.The average comprises 10 short-term price targets ranging from a low of $4.00 to a high of $19.00, with a standard deviation of $4.22. While the lowest estimate ...

Shares of Kamada (KMDA) have gained 1.2% over the past four weeks to close the last trading session at $6.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.75 indicates a potential upside of 113.2%.The average comprises four short-term price targets ranging from a low of $11.00 to a high of $20.00, with a standard deviation of $3.86. While the lowest estimate indicates an ...

The price trend for LENZ Therapeutics, Inc. (LENZ) has been bearish lately and the stock has lost 6.3% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only facto ...

Mesoblast Limited (MESO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individu ...

Shares of Oruka Therapeutics, Inc. (ORKA) have gained 42.7% over the past four weeks to close the last trading session at $27.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $44.89 indicates a potential upside of 63.6%.The average comprises nine short-term price targets ranging from a low of $26.00 to a high of $60.00, with a standard deviation of $9.82. While the lowest est ...

Shares of MBX Biosciences, Inc. (MBX) have gained 2.6% over the past four weeks to close the last trading session at $17.96, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $59 indicates a potential upside of 228.5%.The average comprises eight short-term price targets ranging from a low of $30.00 to a high of $84.00, with a standard deviation of $17.91. While the lowest estimate ...

Simulations Plus (SLP) closed the last trading session at $18.31, gaining 21.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23 indicates a 25.6% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $6.48. While the lowest estimate of $16.00 indicates a 12.6% decline from the current price level, the most optimistic analyst exp ...